Search company, investor...
Kiyatec company logo


Founded Year



Series C - II | Alive

Total Raised


Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+10 points in the past 30 days

About Kiyatec

Kiyatec specializes in modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision-making and drive drug development. Its predictive clinical tests provide oncologists with patient-specific response profiles to the current standard of care drugs prior to treatment selection. The company was founded in 2005 and is based in Greenville, South Carolina.

Headquarters Location

2 N Main St Greenville

Greenville, South Carolina, 29601,

United States


Kiyatec's Product Videos

ESPs containing Kiyatec

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare & Life Sciences / Drug R&D Tech

The organ-on-a-chip market is an innovative field of research focused on creating micro-scale models of human organs using microfluidic technology. This market offers a range of solutions that allow for the simulation of complex biological processes that occur within organs, including drug metabolism, toxicity testing, and disease modeling. By using organ-on-a-chip models, researchers can reduce t…

Kiyatec named as Highflier among 15 other companies, including Emulate, InSphero, and CN Bio Innovations.

Compete with Kiyatec?

Ensure that your company and products are accurately represented on our platform.

Kiyatec's Products & Differentiators

    3D Predict(TM) Glioma

    Kiyatec 3D Predict™ 3D cell culture technology predicts therapeutic response rates >80%2 providing physicians with patient tumor-specific therapeutic response evidence to make informed treatment decisions in effort to improve patient outcomes

Expert Collections containing Kiyatec

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kiyatec is included in 6 Expert Collections, including Medical Devices.


Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health Monitoring & Diagnostics

2,623 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Health IT

7,901 items


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Kiyatec Patents

Kiyatec has filed 11 patents.

The 3 most popular patent topics include:

  • Biological engineering
  • Bioreactors
  • Biotechnology
patents chart

Application Date

Grant Date


Related Topics




Biotechnology, Cell biology, Cell culture, Transcription factors, Stem cells


Application Date


Grant Date



Related Topics

Biotechnology, Cell biology, Cell culture, Transcription factors, Stem cells



Latest Kiyatec News

Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec’s 3D Spheroid Screening Platform, KIYA-PredictTM

May 30, 2023

GREENVILLE, S.C.--(BUSINESS WIRE)--AstraZeneca and Kiyatec, the leader in clinically correlated functional precision oncology, have entered into a multifaceted research agreement to assess therapeutic efficacy of undisclosed preclinical assets using Kiyatec’s 3D spheroid screening platform, KIYA-PredictTM. The agreement to utilize Kiyatec’s spheroid platform aligns with AstraZeneca’s leadership and track record of successfully implementing novel, cutting edge oncology solutions with outside par

Kiyatec Frequently Asked Questions (FAQ)

  • When was Kiyatec founded?

    Kiyatec was founded in 2005.

  • Where is Kiyatec's headquarters?

    Kiyatec's headquarters is located at 2 N Main St Greenville , Greenville.

  • What is Kiyatec's latest funding round?

    Kiyatec's latest funding round is Series C - II.

  • How much did Kiyatec raise?

    Kiyatec raised a total of $29.62M.

  • Who are the investors of Kiyatec?

    Investors of Kiyatec include Brain Tumor Investment Fund, The Sontag Foundation, VentureSouth, LabCorp, Seae Ventures and 10 more.

  • Who are Kiyatec's competitors?

    Competitors of Kiyatec include Xilis, Helomics, WaferGen Bio-systems, Cardium Therapeutics, Rhenovia Pharma and 12 more.

  • What products does Kiyatec offer?

    Kiyatec's products include 3D Predict(TM) Glioma and 1 more.

Compare Kiyatec to Competitors

Bio::Neos Logo

Bio::Neos aims to provide bioinformatics software tools to aid commercial and academic research groups in efficiently and effectively performing genomics-enabled research. The company specialize in mutation identification research and custom software solutions specifically developed to meet the needs of research groups of any size.

Flamma Logo

Flamma specializes in the manufacture of active ingredients and intermediates for the pharmaceutical, nutraceutical and cosmetic industries.

Occam Research

The RDSP was created to help investigators identify funding opportunities and provide assistance to applicants. The RDSP staff work to stimulate research in cancer CAM and design activities that will develop the foundation of the science in cancer CAM research. RDSP programs include a series of Expert Panels on Research Methodologies in Cancer, an Invited Speakers Series, and technical assistance to help investigators prepare grant applications in cancer CAM.


The company's core business is and remains the development and production of Active Pharmaceutical Ingredient and parenteral formulations in the the form of solution and Lyophilized injection, in areas like anesthialogy and oncology.


EMTech, a spin-off of BiOva, LLC, is researching, developing, and manufacturing technologies for the metabolic enhancement of the enzymes and bacteria used in the fermentation industry. The company's current products and ongoing research projects show applications that enhance productivity in the ethanol, pharmaceutical, beer, wine, and dairy industries.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.